Nov 14 (Reuters) - German drugmaker Evotec EVTG.DE is attracting takeover interest from U.S.-based Halozyme Therapeutics HALO.O, Bloomberg News reported on Thursday.
Halozyme has recently expressed interest in acquiring Evotec at about 11 euros per share, the report added, citing people familiar with the matter.
Earlier this week private equity firm Triton was also reportedly exploring a potential buyout of Evotec, after it confirmed a close to 10% stake in the company.
Evotec's other major shareholders are Novo Nordisk NOVOb.CO parent Novo Holdings and Mubadala Investment.
Evotec's shares have fallen about 60% this year as revenues continue to slump due to weakness in the clinical research organization business market environment.
The company collaborates with biotech companies through research alliances and development partnerships to help with drug development.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
((Christy.Santhosh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。